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Abstract
Introduction: Necrotizing autoimmune myopathies (NAM) have recently been defined as a distinct group of severe
acquired myopathies, characterized by prominent myofiber necrosis without significant muscle inflammation.
Because of the lack of appropriate biomarkers, these diseases have been long misdiagnosed as atypical forms of
myositis. NAM may be associated to autoantibodies directed against signal recognition particle (SRP) or 3-hydroxy-
3-methyl-glutaryl-CoA reductase (HMGCR). The objective of this work was to quantify anti-HMGCR autoantibodies in
patients with suspicion of NAM through the development of a new addressable laser bead immunoassay (ALBIA).
Methods: Recombinant HMGCR C-domain was bound to fluorescent beads. After incubation with serum, autoantibodies
were revealed using class- or subclass-specific anti-human immunoglobulin G (IgG) antibodies. Anti-HMGCR levels were
assayed in 150 patients with suspicion of NAM, 142 controls with different inflammatory/autoimmune diseases and 100
healthy donors. Inhibition with free recombinant HMGCR and immunoprecipitation experiments confirmed test
specificity. Reproducibility and repeatability were determined from sera with various levels of anti-HMGCR autoantibodies.
A multiplex assay (ALBIA-NAM) was also developed to permit the simultaneous quantification of anti-HMGCR
and anti-signal recognition particle autoantibodies.
Results: No controls scored positive. Of 150 patients with suspicion of NAM, 24% were positive for anti-HMGCR
autoantibodies with levels ranging from 24 to 2,656 AU/mL. Anti-HMGCR positivity could be associated to a
cytoplasmic pattern in immunofluorescence assay on HEp-2 cells. Anti-HMGCR-positive patients had high creatine kinase
(CK) levels (mean 6,630 IU/L) and only 40% of them had been exposed to statins. Multiplex ALBIA-NAM was equally
as effective as monoplex anti-HMGCR and anti-SRP ALBIA.
Conclusions: Both monoplex ALBIA-HMGCR and multiplex ALBIA-NAM reliably detect and quantify anti-HMGCR
autoantibodies. A positive result allows ascribing patients with a necrotizing myopathy to an autoimmune form.
Anti-HMGCR autoantibodies may be found in patients who have not taken statins.
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Introduction
Inflammatory myopathies are a heterogeneous group
of acquired muscle disorders including polymyositis,
dermatomyositis, inclusion body myositis and overlap
myositis. Recently, necrotizing autoimmune myop-
athies (NAM) have been defined as a distinct group of
severe acquired myopathies, characterized by patho-
logical features of prominent myofiber necrosis with-
out significant inflammation [1]. Because of the lack of
appropriate biomarkers, these diseases have been long
misdiagnosed as atypical forms of myositis with little if
any inflammation [2-4]. With the emergence of reports
describing clinical cases of necrotizing myopathy with
microangiopathy and microvascular deposition of com-
plement [5], they were progressively distinguished from
myositis and finally classified as NAM by a collaborative
study group in 2004 [6]. NAM may be associated with auto-
antibodies (aAbs) such as anti-signal recognition particle
(SRP) autoantibodies. Anti-SRP aAbs are present in a minor-
ity (4 to 6%) of patients with acquired inflammatory and/or
necrotizing myopathies [6-10] and are associated with severe
clinical forms, particularly with heart involvement [11,12].
In 2007, Needham et al. reported eight patients who devel-
oped a myopathy during statin therapy [13]. Histological
analysis of muscle biopsies revealed necrotic and regenerat-
ing myofibers. Later, aAbs against a 100 kDa protein were
characterized and finally identified by Mammen et al. as di-
rected against 3-hydroxy-3-methylglutaryl-coenzyme A re-
ductase (HMGCR), a key enzyme of the cholesterol
biosynthesis pathway, which is pharmacologically inhibited
by statins [14,15].
The diagnosis of NAM may be difficult, notably in slowly
progressive forms in young adults, since histopathological
features mimic some forms of muscular dystrophies and
some patients may remain without diagnosis for years.
Hence, the detection of aAbs in patients with undeter-
mined necrotizing myopathy is of utmost importance to
indicate an autoimmune mechanism and therefore guide
appropriate therapy. Currently, the detection of anti-SRP
autoantibodies is based on indirect immunofluorescence
on HEp-2 cells, followed by confirmation using a dot-blot
test or a quantitative addressable laser bead immunoassay
(ALBIA) [16,17]. Here, we developed a new ALBIA for the
detection and titration of anti-HMGCR aAbs (ALBIA-
HMGCR) as a biomarker of NAM. Also, in order to pro-
vide a unique test for the diagnosis of aAb-associated
NAM, we further developed a multiplex assay (ALBIA-
NAM) and determined whether it could discriminate pa-
tients with anti-HMGCR and anti-SRP aAbs.
Material and methods
Serum samples
In this medical research, where we used identifiable hu-
man sera and data, we obtained agreement from the
French Ministry of Research (AC 2008-87) for the col-
lection, analysis, storage and reuse. All samples were ob-
tained for diagnostic purposes only with no extra
sampling and, in this situation of retrospective study, pa-
tients’ consent was not required. The research protocol
was approved by research ethics committee of Pitié-
Salpêtrière University Hospital.
Serum or blood samples (n = 150 patients) that were
sent to the Laboratory of Immunology of Rouen University
Hospital for analysis of anti-HMGCR aAbs because of
suspicion of NAM were analyzed. These samples were ob-
tained between August 2012 and January 2013 from 24
French centers and were all negative for anti-Jo-1 and
anti-SRP aAbs. All patients who were found positive for
anti-HMGCR aAbs were negative for anti-PL-7 and anti-
PL-12 aAbs. For these anti-HMGCR-positive patients, the
following parameters were recorded from their medical
reports: age, sex, past medical history, statin exposure,
characteristics of myopathy including clinical manifest-
ation and muscular deficit evaluation by muscle manual
testing using the Medical Research Council scale on five
points, and creatine kinase (CK) level at the date of the
anti-HMGCR assay. Special emphasis was performed by
the clinician to check statin exposure during follow-up
medical consultations. For correlation experiments, we
additionally analyzed 25 anti-SRP-positive sera that were
described previously [16]. The term SRP in text and
figures refers to the 54 kDa subunit of the multimeric
SRP complex.
Control sera were collected from 100 healthy blood
donors and from 142 patients with different inflamma-
tory/autoimmune diseases, according to established clas-
sification criteria: American College of Rheumatology
(ACR) revised criteria for systemic lupus erythematosus
(SLE) [18] with anti-double-stranded DNA (dsDNA)
aAbs (n = 19), American Rheumatism Association
(ARA) criteria for rheumatoid arthritis (RA) [19] with
anti-cyclic citrullinated peptide (CCP) antibodies and/
or rheumatoid factor (n = 18), revised European criteria
for primary Sjögren’s syndrome [20] with anti-SSA and/or
anti-SSB aAbs (n = 15), Bohan and Peter criteria [21] for
dermatomyositis (DM) (n = 8), Troyanov criteria for over-
lap myositis [10] with anti-tRNA-synthetase Ab (anti-Jo-1,
n = 27; anti-PL-7, n = 1; anti-PL-12, n = 2) and Griggs cri-
teria for inclusion body myositis (IBM) [22] (n = 30).
Another control consisted in sera from patients with poly-
clonal hypergammaglobulinemia (serum immunoglobulin
(Ig)G: 23.1 ± 6.9 g/L, mean ± standard deviation (SD)) (n =
24). All serum samples were stored at −80°C until use.
Western blot analysis of recombinant C-terminal domain
of the HMGCR protein
The catalytic C-domain (amino acids 441 to 880) of hu-
man HMGCR protein fused to a glutathione S-transferase
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(GST) tag was obtained from Sigma-Aldrich (St Louis,
MO, USA). Purity of this recombinant HMGCR protein
was first determined by 4 to 10% gradient sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
under nonreducing conditions, followed by Coomassie
Blue staining. Western blot analysis was further per-
formed by transfer of proteins separated by nonreduc-
ing SDS-PAGE to a nitrocellulose membrane followed
by incubation with rabbit anti-HMGCR Abs (Abcam,
Cambridge, MA, USA) or a human anti-HMGCR-
positive serum and revelation with corresponding sec-
ondary antibody coupled to Alexa Fluor 680 (Invitrogen,
Cergy Pontoise, France).
Immunoprecipitation of human recombinant HMGCR with
patients’ sera
Immunoprecipitation was performed by adding 20 μl of
human serum sample or 1 μg of positive control rabbit
anti-HMGCR Ab to 10 μg of recombinant HMGCR
C-domain and bringing the volume to 0.5 ml of IP
buffer (1% Nonidet P40, 20 mM Tris pH 7.4, 150 mM
NaCl, 1 mM EDTA) and rotating the mix for 2 h at 4°C.
Protein G agarose beads (Pierce, Rockford, IL, USA) were
added for an additional hour. Then, immunoprecipitates
were boiled in the presence of Laemmli buffer and sub-
sequently electrophoresed on 4 to 10% gradient SDS-
PAGE under reducing conditions. Immunoprecipitated
HMGCR was revealed with a rabbit anti-HMGCR Ab
coupled to Alexa Fluor 680 and read on an Odyssey Li-
Cor (Li-Cor Biosciences, Lincoln, NE, USA).
Addressable laser bead immunoassay (ALBIA) for the
detection and quantification of anti-HMGCR aAbs
(ALBIA-HMCGR)
We previously described an ALBIA for anti-SRP anti-
bodies (ALBIA-SRP) [16]. Here, to develop immunoassay
for anti-HMGCR antibodies (ALBIA-HMGCR), a similar
strategy was applied with some modifications. Five to
12 μg of recombinant HMGCR C-domain were coupled
to 1.25 × 106 fluorescent Bio-Plex™ COOH-microspheres
(Bio-Rad, Hercules, CA, USA) with the Bio-Plex™ amine
coupling kit (Bio-Rad) according to manufacturer’s proto-
col. After optimization to maximize the signal/noise ratio,
the quantity of HMGCR protein per coupling reaction
was set at 10 μg. After coupling, coated beads were either
used immediately or stored at −20°C in the dark. When
indicated, a human recombinant SRP or intrinsic factor
protein (Diarect AG, Freiburg, Germany) was used in
place of HMGCR for controls.
Immediately prior to use, HMGCR-coated beads were
vigorously agitated for 30 s. Then, a 10 μl volume con-
taining 1,250 beads was added to 100 μl of serum from
patients or controls (diluted in Dulbecco's phosphate-
buffered saline (DPBS) plus 1% fetal bovine serum) in
Multiscreen 96-well plates (Millipore, Bedford, MA, USA).
Plates were incubated for 2 h at room temperature in the
dark on a plate shaker at 650 rpm. Blank (no serum, sec-
ondary antibody only), negative control (anti-HMGCR
negative serum) and positive controls (highly positive hu-
man anti-HMGCR Ab serum or rabbit anti-HMGCR Abs
with appropriate secondary antibody) were included in
every assay. Beads were collected by filtration under vac-
uum and washed twice with 150 μl DPBS containing 0.1%
Tween-20. Biotinylated mouse anti-human IgG- or isotype
(IgG1, IgG2, IgG3 or IgG4)-specific secondary Ab
(Southern Biotech, Birmingham, AL, USA) were added
at 1/2,000 dilution and incubated for 1 h at room
temperature under shaking. After washing, beads were
incubated with 50 μl of streptavidin-R-phycoerythrin
(Qiagen, Venlo, The Netherlands) at 1/1,000 dilution
for 15 min. Finally, beads were resuspended in 100 μl
of DPBS and mean fluorescence intensity (MFI) was
determined on a Bio-Plex™ apparatus using the Bio-Plex™
Manager software 4.0 (Bio-Rad).
The analytical sensitivity of detection of ALBIA-
HMGCR was determined by triplicate dosage of serial
dilutions of rabbit anti-HMGCR antibodies. For each
well, after subtraction of negative control MFI value,
mean MFI and standard deviation (SD) were calculated.
The analytical specificity of detection of ALBIA-
HMGCR was determined by using high-level human
anti-HMGCR, anti-SRP or anti-intrinsic factor positive
sera at 1/1,000 dilution. Sera were incubated with puri-
fied HMGCR, SRP or intrinsic factor beads for 1 h at
room temperature and MFI was determined as described
above.
Specific inhibition of ALBIA-HMGCR was performed
using increasing concentrations of recombinant HMGCR
protein, with 1/2,000 dilution of the anti-HMGCR serum
used as 100% reference. Percent inhibition was calculated
as (1 - (MFI pre-adsorbed serum/MFI serum)) × 100.
Homologous and heterologous inhibition of ALBIA-
HMGCR was further performed by pre-absorption of
three anti-HMGCR, three anti-SRP or three anti-intrinsic
factor positive sera with 100 μg/ml of recombinant
HMGCR, SRP or intrinsic factor protein.
All patients' sera were initially assayed at a 1/500 dilu-
tion. The anti-HMGCR Ab levels were determined at a
1/D dilution using the following formula: (MFIserum/
MFIcalibrator) × (level of calibrator) × D/500. The cali-
brator is a human highly positive anti-HMGCR
serum (the same throughout the study) whose level
was arbitrarily set to 100 arbitrary units (AU)/mL).
When sample MFI at 1/500 dilution was higher than
80% of calibrator MFI, further dilutions were per-
formed and the first dilution yielding a MFI inferior
to 80% of calibrator MFI was retained for calculation
of level.
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Reproducibility of ALBIA-HMGCR was determined
using three independent anti-HMGCR Ab positive sera
(low, medium and high level). Intra-assay variation was
determined by measurements of the same samples within
the same run. Inter-assay variation (assay to assay) was
determined by measurements of the same samples in
separate runs. Inter-assay variation (batch to batch)
was determined by measurement of the same samples
in the same run using different batches of coupled
beads. Coefficients of variation (CV) were computed
as SD/mean.
Multiplex ALBIA for the simultaneous detection and
quantification of anti-HMGCR and anti-SRP aAbs in NAM
patients (ALBIA-NAM)
To detect simultaneously anti-SRP or anti-HMGCR
aAbs from a single sample, we used two different beads
harboring a special mixture of red/infrared dyes so that
they are endowed with a specific spectral signature.
Color codes of HMGCR- and SRP-coupled beads were
number 55 and 28 (Bio-Rad), respectively. After coup-
ling with HMGCR or SRP, 10 μl of each bead prepar-
ation were mixed and incubated with serum samples in
the same conditions than described previously. Analyt-
ical specificity of ALBIA-NAM was further determined
by analyzing sera from patients with anti-HMGCR or
anti-SRP aAbs or from healthy controls or patients
with different inflammatory/autoimmune conditions
including RA, systemic sclerosis, SLE, DM, anti-tRNA
synthetase aAb positive myositis and IBM, or poly-
clonal hypergammaglobulinemia. Levels of anti-SRP
and anti-HMGCR sera were compared with those ob-
tained with the corresponding monoplex ALBIA-HMGCR
or ALBIA-SRP.
HMGCR line immunoassay and immunofluorescence analysis
The Myositis Euroline 7 (IgG) line immunoassay was
kindly provided by Euroimmun (Lübeck, Germany). It
consists in a membrane strip coated with different anti-
gens, including two different recombinant HMGCR pro-
teins. The first consists of the HMGCR C-domain fused
to GST and the second a human cDNA expressed in
Escherichia coli. The assay was used according to the
manufacturer’s instruction and the intensity of color-
ation was graded from one to four.
Indirect immunofluorescence was performed on HEp-
2000™ cells (ImmunoConcepts, Sacramento, CA, USA)
and Kallestad HEp-2 cells (Bio-Rad). Sera were tested at
1/80 screening dilution in PBS buffer, using a FITC-
coupled antibody against human IgG.
Statistical analysis
The normality of data distribution was analyzed using the
D'Agostino and Pearson test, and the receiver operating
characteristic (ROC) curve was determined using Prism
software (GraphPad Software, La Jolla, CA, USA).
Results
Sensitivity and specificity of ALBIA-HMGCR
To allow quantitative analysis of anti-HMGCR aAbs in
patients, we developed an addressable laser bead im-
munoassay (ALBIA-HMGCR) [16,23]. For this, we used
as antigen the recombinant catalytic C-domain of the
human HMGCR protein fused to GST. Purity of this
protein was confirmed by Coomassie blue staining after
SDS-PAGE, revealing a unique band (Figure 1A) that
was specifically recognized by rabbit anti-HMGCR Abs
or a human anti-HMGCR positive serum in Western
blot (Figure 1B).
HMGCR was coupled through a covalent link to fluor-
escent beads and used to measure the levels of anti-
HMGCR Abs. The development of ALBIA-HMGCR
first required optimizing concentration of recombinant
HMGCR protein used to coat beads, incubation times,
washing steps and revelation with the secondary anti-
body (not shown, see Material and Methods for details).
This yielded a method allowing detection of as low as
5 ng/mL anti-HMGCR Abs (Figure 1C), indicating a
very good analytical sensitivity of the assay.
The specificity of HMGCR-coated beads was next
evaluated. For this, HMGCR, SRP and intrinsic factor-
specific beads were prepared and analyzed using a hu-
man anti-HMGCR, anti-SRP or anti-intrinsic factor
positive serum. Only anti-HMGCR but not irrelevant
anti-SRP or anti-intrinsic factor Ab-positive sera reacted
with HMGCR beads (Figure 2A). Similarly, beads coated
with SRP or intrinsic factor recombinant proteins that
were produced and purified using the same process that
for HMGCR protein reacted only with the correspond-
ing aAb-positive serum.
Addition of free homologous protein, that is HMGCR,
resulted in a dose-dependent inhibition of the HMGCR
signal (Figure 2B) while no inhibition was observed
when using a heterologous protein, that is SRP or intrin-
sic factor, at the concentration of 100 μg/mL (Figure 2C).
To further confirm the antigenic specificity of the assay,
five sera that scored positive for anti-HMGCR aAbs
using ALBIA-HMGCR were used to immunoprecipitate
the recombinant HMGCR protein. This yielded a posi-
tive result in 5/5 cases but not when using an irrelevant
serum (Figure 2D).
Determination of anti-HMGCR aAb levels
The method used for calculating anti-HMGCR levels is
illustrated in an additional figure (see Additional file 1).
The serum used in this example showed a saturating sig-
nal at the 1/500 screening dilution. A further 1/4,000 di-
lution was retained to calculate the level by reference to
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a highly positive anti-HMGCR serum used as calibrator
whose level was arbitrarily set to 100 AU/mL.
Reproducibility and repeatability of the ALBIA-HMGCR
Reproducibility and repeatability of the test were deter-
mined by calculating both intra- and inter-assay variation
for sera with high, medium and low anti-HMGCR levels.
The intra-assay coefficients of variation (CV) ranged from
5% for high/medium levels to 13% for low levels, as indi-
cated in an additional table (see Additional file 2).
Similarly, the mean CV for inter-assay variation, as deter-
mined from plate-to-plate or batch-to-batch variations
ranged from 9 to 11%, and 2.8 to 5.6%, respectively. To-
gether, these data indicate a good reproducibility and re-
peatability of the ALBIA-HMGCR assay.
Validation of ALBIA-HMGCR
We used ALBIA-HMGCR to screen serum samples for
the presence of anti-HMGCR aAbs. First, a threshold of
positivity was calculated using 100 control sera from
Figure 1 Development of a quantitative assay for the detection of anti-HMGCR antibodies. (A) SDS-PAGE analysis of the recombinant
HMGCR catalytic C-domain after Coomassie blue staining. (B) Western blot analysis of this recombinant HMGCR using a specific rabbit anti-HMGCR
antibody or a human anti-HMGCR-positive serum. (C) Addressable laser bead immunoassay (ALBIA-HMGCR) using serial dilutions of rabbit anti-HMGCR
antibody. The mean fluorescence intensity (MFI) values are the mean of triplicate determinations. Standard deviation (SD) errors bars are not visible
because of very low variability (coefficients of variation SD/mean lower than 1%, range (0.0025 to 0.7525)). Insert, higher magnification for
the low anti-HMGCR antibody concentrations (horizontal dotted line depicts mean + 2 SD of 20 negative controls). HMGCR, 3-hydroxy-3-methylglutaryl
coenzyme A reductase.
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healthy blood donors. The values obtained with control
sera did not follow a normal distribution (P <0.0001),
their median was 0 AU/mL and the 99th percentile was
14 AU/mL. At a cutoff of 14 AU/mL, 99/100 control
sera scored negative (Figure 3A).
Next, we analyzed sera from 150 patients with suspi-
cion of NAM. Of these, 37 patients (24%) were anti-
HMGCR positive, with levels ranging from 24 to
2.656 AU/mL. ROC curve analysis revealed a specifi-
city of 100% and a sensitivity of 100% when the cutoff
was set at 20 AU/ml (Figure 3B). Patients with differ-
ent inflammatory/autoimmune conditions including
RA, systemic sclerosis, SLE, DM, anti-tRNA synthetase
Ab positive myositis or IBM, as well as patients with
polyclonal hypergammaglobulinemia all scored negative
(Figure 3A). Anti-HMGCR positive and 16 negative sera
from healthy donors were further tested by a recently de-
veloped line immunoassay. All 37 ALBIA-HMGCR posi-
tive sera were positive using this assay while 16/16 controls
were negative (not shown). Yet, there was no correlation
between band intensity and ALBIA-HMGCR level.
Immunofluorescence aspect on HEp-2 cells
Sixty-one percent (20/33) of ALBIA-HMGCR positive
sera displayed a finely granular cytoplasmic pattern on a
minority (3% or less) of HEp-2000® cells (Figure 4). This
immunoreactivity could be inhibited by previous incuba-
tion with free HMGCR. Using Kallestad HEp-2 cells,
only 30% of the ALBIA-HMGCR positive sera yielded
this aspect (not shown).
IgG isotypes of anti-HMGCR Abs
Fifteen ALBIA-HMGCR positive sera were tested for anti-
HMGCR IgG subclasses. Only IgG1 were represented
among anti-HMGCR aAbs in this series (not shown).
IgG2, IgG3 or IgG4 subclasses were never found, neither
as a single isotype nor in association with IgG1.
Exploring necrotizing autoimmune myopathies with
multiplex ALBIA-NAM
In order to simultaneously quantify anti-HMGCR and
anti-SRP aAbs, we next developed a multiplex assay
(ALBIA-NAM) and compared its results to that of
monoplex ALBIA-HMGCR and ALBIA-SRP [16]. For
this, we assayed 26 anti-HMGCR positive patients from
the present series plus 25 anti-SRP positive sera that
were described previously [16]. Results from both assays
were compared by linear regression and showed excel-
lent correlation, with R values of 0.9942 and 0.9937 for
Figure 2 Specificity of HMGCR-coated beads. (A) HMGCR, signal recognition particle (SRP) and intrinsic factor-specific beads were coupled to
the corresponding recombinant protein and analyzed by ALBIA using a human anti-HMGCR, anti-SRP or anti-intrinsic factor positive serum.
(B) Dose-dependent inhibition of human anti-HMGCR antibodies binding to HMGCR-coated beads by free human recombinant HMGCR
protein. Percent inhibition is given relative to the mean fluorescence intensity (MFI) value in the absence of free HMGCR. (C) Specific inhibition
by homologous HMGCR but not heterologous proteins. Percent inhibition of three different human anti-HMGCR positive sera (referred to as #1,
#2 and #3) by 100 μg/mL of free HMGCR, SRP or intrinsic factor proteins. (D) Immunoprecipitation of HMGCR protein by ALBIA-HMGCR
positive or negative human sera. A rabbit anti-HMGCR polyclonal antibody was used as positive control. ALBIA, addressable laser bead
immunoassay; HMGCR, 3-hydroxy-3-methylglutaryl coenzyme A reductase.
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ALBIA-HMGCR versus ALBIA-NAM (Figure 5A) and
ALBIA-SRP versus ALBIA-NAM (Figure 5B), respectively.
ALBIA-NAM revealed able to perfectly discriminate
the two populations of NAM patients, that is those with
anti-HMGCR from those with anti-SRP aAbs (Figure 5C)
and was negative for all other tested conditions, that is
patients with different inflammatory/autoimmune condi-
tions, DM, anti-tRNA synthetase Ab positive myositis or
IBM, as well as patients with polyclonal hypergammaglo-
bulinemia (see Additional file 3). The sensitivity of mono-
plex and multiplex assays was equivalent. No NAM
patient was positive for both aAbs.
Characteristics of anti-HMGCR positive patients
Characteristics of anti-HMGCR positive patients are sum-
marized in Table 1. These patients presented with proximal
muscle weakness (92%), had elevated (mean >6,000 IU/L)
CK levels and 60% had not taken statins. Muscle biopsies
always showed regenerating and necrotic muscle fi-
bers, with occasionally (28%) perivascular inflamma-
tory infiltrates.
Discussion
This report describes the first immunoassay which can
detect and quantify simultaneously anti-HMGCR and
anti-SRP aAbs in patients with NAM, a recently identified,
severe form of inflammatory myopathy with important
muscle necrosis/regeneration and little inflammation. Up
to recently, the first aAb sought for in NAM patients was
directed against SRP, a protein complex that guides the
translocation of growing polypeptides into the endoplas-
mic reticulum during protein synthesis. Currently, the
Figure 4 Aspect of anti-HMGCR autoantibodies in indirect immunofluorescence on HEp-2 cells. Classical indirect immunofluorescence
assay using the HEp-2000™ line as cellular substrate. After incubation of serum at a 1/80 dilution, immunoreactivity was revealed by a FITC-labeled
anti-human immunoglobulin (Ig)G secondary antibody. Example from two representative anti-HMGCR positive patients out of 20/33 sera with this
immunofluorescence pattern shows a finely granular cytoplasmic staining with perinuclear reinforcement (left and middle). Inhibition by free
HMGCR protein before immunofluorescence (right): the serum from example 2 was pre-incubated with free HMCGR before immunofluorescence
assay. This yielded an extinction of immunoreactivity. HMGCR, 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Figure 3 Validation of ALBIA-HMGCR and determination of anti-HMGCR levels in patients with suspicion of NAM. (A) A positivity cutoff
of the assay was first determined as the 99th percentile (14 arbitrary units (AU)/mL) of the healthy donors’ distribution (open circles) and depicted
by a dotted line. Sera from patients with different inflammatory/autoimmune conditions including rheumatoid arthritis (RA), systemic sclerosis
(SS), systemic lupus erythematosus (SLE), dermatomyositis (DM), anti-tRNA synthetase-positive myositis or inclusion body myositis (IBM), as well as
patients with polyclonal hypergammaglobulinemia were assayed and revealed all negative. Insert is a magnification for low values. Thirty-seven
out of 150 (24%) of serum samples from patients with suspicion of NAM scored positive using ALBIA-HMGCR. (B) Receiver operating characteristic
(ROC) analysis was performed by comparing the 37 anti-HMGCR positive serum samples to those from healthy donors. Optimal results were obtained
with a cutoff of 20 AU/mL, which was indicated as a plain line. ALBIA, addressable laser bead immunoassay; HMGCR, 3-hydroxy-3-methylglutaryl
coenzyme A reductase; NAM, necrotizing autoimmune myopathies.
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detection of anti-SRP aAbs may be suspected upon result
of an indirect immunofluorescence test and the diagnosis
must be confirmed by a specific assay, for example dot-
blot. Recently, we described a new immunoassay, that is
ALBIA-SRP, to quantify anti-SRP aAbs and investigated
the relationship between serum CK levels, muscle strength
and anti-SRP levels [16]. Results revealed a significant
correlation between the degree of myolysis and the level
of anti-SRP aAbs, suggesting that these aAbs may be
pathogenic. In the present study, we applied a similar
strategy to provide a new immunoassay for anti-HMGCR
aAbs, and also validated a multiplex immunoassay to de-
tect and quantify both anti-HMGCR and anti-SRP aAbs
using a single biological test.
Whereas it cannot be excluded that some other epi-
topes might exist, a mapping study showed that anti-
HMGCR aAbs recognize the catalytic C-domain of
HMGCR, but do not react with the N-terminal domain
of the protein [15]. Hence, beads were coated with a re-
combinant HMGCR C-domain protein. Rabbit anti-
HMGCR Abs that were produced after immunization
with a polypeptide corresponding to residues 550 to 650
of the human HMGCR C-domain could recognize the
recombinant protein used herein for performing Western
blot (Figure 1B) and ALBIA-HMGCR (Figure 1C). These
results demonstrate the accessibility of recombinant
HMGCR C-domain epitopes to anti-HMGCR Abs.
The reactivity of the human anti-HMGCR positive
serum against some smaller bands (approximately 40
to 45 kDa) in the Western blot (Figure 1B) presumably
indicates that the recombinant HMGCR antigen has
some breakdown products that are not recognized by
the rabbit serum that was obtained by immunization
with only a fragment of HMCGR C-domain.
ALBIA-HMGCR detected anti-HMGCR aAbs in 37
individuals (24%) among a series of 150 patients with
suspicion of NAM (Figure 3A). A perfect concordance
with a recently developed line immunoassay was found.
Yet, there was no correlation between band intensity in
this assay and ALBIA-HMGCR level. Further, ALBIA-
HMGCR remained negative when tested against sera
from patients with different inflammatory/autoimmune
conditions including RA, systemic sclerosis, SLE, DM,
anti-tRNA synthetase-positive myositis or IBM, or in pa-
tients with polyclonal hypergammaglobulinemia (Figure 3A).
ROC analysis revealed a cutoff for positivity of 20 AU/mL,
providing a high diagnostic value (Figure 3B).
Anti-HMGCR IgG subclass distribution, which had
remained unknown until now, was determined. Contrary
to what was observed for anti-SRP positive patients in
whom IgG1 and IgG4 were principally observed while
Figure 5 Comparison of monoplex ALBIA-HMGCR and ALBIA-SRP
to multiplex ALBIA-NAM. Serum from anti-HMGCR positive (n = 26)
or anti-SRP positive (n = 25) patients were compared. (A) Correlation
of the signals generated by ALBIA-NAM versus ALBIA-HMGCR. Mean
fluorescence intensity (MFI) (B) Correlation of the signals generated by
ALBIA-NAM versus ALBIA-SRP. (C) ALBIA-NAM discriminates anti-SRP
positive from anti-HMGCR positive patients in a single assay. ALBIA,
addressable laser bead immunoassay; HMGCR, 3-hydroxy-3-methylglutaryl
coenzyme A reductase; SRP, signal recognition particle.
Table 1 Clinical characteristics of anti-HMGCR positive
patients (n = 37)
Age (mean ± SD): 44 ± 19 years
Sex (M/F): 12/25
Muscle weakness: 34/37 (92%)
Creatine kinase level (mean ± SD): 6,974 ± 4,970 IU/L
Statin exposure: 15/37 (40%)
HMGCR, 3-hydroxy-3-methylglutaryl coenzyme A reductase; SD, standard
deviation.
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all four subclasses could possibly be found depending on
the patient [16], or to other autoimmune diseases such
as myasthenia gravis, membranous glomerulonephritis
or pemphigus, in which both IgG1 and IgG4 isotypes
have been found [24-26], the only subclass detected in
anti-HMGCR positive patients was IgG1 in the present
study.
Using immunofluoresence on HEp-2 cells, 30 to 61%
of anti-HMGCR positive sera exhibited a finely granular
cytoplasmic pattern with perinuclear reinforcement in a
minority of cells (Figure 4). Yet, the cellular substrates
used for immunofluorescence appeared heterogeneous
in terms of HMGCR expression levels and some com-
mercial sources may provide HEp-2 cells less prone to
allow detecting anti-HMGCR aAbs than others.
Christopher-Stine et al. found a 7% prevalence of anti-
HMGCR aAbs (as initially determined by a 100 to
200 kDa reactivity after immunoprecipitation) within a
series of 225 patients with proximal muscle weakness,
elevated CK, myopathic findings on electromyography,
muscle edema on magnetic resonance imaging and/or
features of myopathy on muscle biopsy [14]. This preva-
lence was higher in a subgroup of 38 patients with nec-
rotizing myopathy among whom 16 (42%) were found
positive for anti-HMGCR aAbs.
In a general population of statin users, with or without
self-limited musculoskeletal side effects, the prevalence
of anti-HMGCR aAbs is extremely low [27]. In contrast,
Mammen et al. reported that 67% of anti-HMGCR posi-
tive NAM patients had been exposed to statins [14,15].
Here, we found that 40% of our anti-HMGCR positive
patients had taken statins. Therefore, although anti-
HMGCR aAbs are directed against the statins target it-
self, the diagnosis of anti-HMGCR positive NAM should
not be excluded a priori in patients who have not been
exposed to statins.
An advantage of the ALBIA methodology is to allow the
concomitant detection of several aAbs in a single assay
from a unique serum sample, therefore reducing number
of biological tests, labor and time necessary between diag-
nosis and therapy. In this study, we multiplexed ALBIA-
HMGCR and ALBIA-SRP to provide the multiplex
ALBIA-NAM. The performance of ALBIA-NAM was
compared to that of the parental monoplex immunoassays.
Linear regression analysis showed an excellent correlation
between monoplex and multiplex assays (Figure 5A,B).
None of the sera found positive by monoplex assays scored
negative when using ALBIA-NAM and vice versa. Further-
more, all anti-HMGCR positive sera were negative for
anti-SRP aAbs, suggesting that patients with anti-SRP or
anti-HMGCR aAb might belong to different NAM sub-
groups (Figure 5C). Yet, a fraction of NAM patients re-
mains without any known aAb, suggesting that new
auto-antigenic specificities are still to be discovered.
Together, the results of this study show that multiplex
ALBIA-NAM allows efficient detection and quantifica-
tion of anti-HMGCR or anti-SRP aAbs in patients with
suspicion of NAM and that the diagnosis of anti-
HMGCR positive NAM should not be excluded a priori
in patients who have not been exposed to statins.
Conclusions
Diagnosis and clinical studies of necrotizing auto-
immune myopathies (NAM) have been hampered by the
paucity of biological assays for the assessment of specific
biomarkers. Some NAM patients have autoantibodies
(aAbs) against the statins drug target, that is 3-hydroxy-
3-methyl-glutaryl-coenzyme A reductase (HMGCR). Here,
we developed a new immunoassay allowing efficient detec-
tion and quantification of anti-HMGCR aAbs in patients
with suspicion of NAM. In a series of 150 patients, 24%
were found positive for anti-HMGCR aAbs. Only 40% of
anti-HMGCR-positive patients had been exposed to statins.
Hence, lack of statin exposure should not eliminate the diag-
nosis of anti-HMGCR-positive NAM. This assay was multi-
plexed with an anti-signal recognition particle (SRP) aAb
immunoassay, facilitating the diagnosis of NAM using a sin-
gle assay.
Using indirect immunofluorescence, some anti-HMGCR
positive sera exhibited a finely granular cytoplasmic pattern
with perinuclear reinforcement in a minority of cells. Nec-
rotizing myopathies may also encompass some forms of
muscular dystrophy. Together, the present assays will be
helpful for the diagnosis of necrotizing myopathies since a
positive result allows ascribing patients to an autoimmune
form.
Additional files
Additional file 1: Determination of the level of anti-HMGCR aAbs.
Anti-HMGCR levels were determined by reference to the MFI value, in
the same assay, of a calibrator that is, a highly positive anti-HMGCR +
serum whose level was arbitrarily set to 100 AU/mL. The assay was first
performed using a 1/500 screening dilution of the serum. In this example,
the sample’s MFI at a 1/500 dilution was higher than 80% of the calibrator’s
MFI. Thus, further dilutions were performed and the first dilution yielding a
MFI inferior to 80% of the calibrator MFI was retained for calculation,
yielding a 428 AU/mL anti-HMGCR level. aAbs, autoantibodies; AU, arbitrary
units; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; MFI, mean
fluorescence intensity.
Additional file 2: Reproducibility of ALBIA-HMGCR. Intra- and inter-
assay reproducibility as determined by the coefficients of variation (CV
%) for repeated measures of high, medium and low anti-HMGCR level
samples. ALBIA, addressable laser bead immunoassay; HMGCR, 3-
hydroxy-3-methylglutaryl-coenzyme A reductase.
Additional file 3: Validation of ALBIA-NAM. A positivity cutoff of the
multiplex assay (dotted line) was determined as the 99th percentile of
the healthy donors’ distribution (open circles) for both (A) anti-SRP (9 AU/mL)
and (B) anti-HMGCR aAbs (8 AU/mL). Sera from patients with different
inflammatory/autoimmune conditions including rheumatoid arthritis
(RA), systemic sclerosis (SS), systemic lupus erythematosus (SLE), dermatomyositis
(DM), anti-tRNA synthetase aAb-positive myositis or inclusion body myositis
Drouot et al. Arthritis Research & Therapy 2014, 16:R39 Page 9 of 11
http://arthritis-research.com/content/16/1/R39
(IBM), as well as patients with polyclonal hypergammaglobulinemia were
assayed. aAbs, autoantibodies; ALBIA, addressable laser bead immunoassay; AU,
arbitrary units; HMGCR, 3-hydroxy-3-methylglutaryl coenzyme A reductase; NAM,
necrotizing autoimmune myopathies; SRP, signal recognition particle.
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